Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEWARK, CA / ACCESS NEWSWIRE / AUGUST 18, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) TODAY REPORTED THAT ON AUGUST 17, 2026, IT GRANTED INDUCEMENT AWARDS TO TWO RECENTLY HIRED EMPLOYEES IN ACCORDANCE WITH THE TERMS OF THEIR EMPLOYMENT OFFER LETTERS. THE AWARDS WERE GRANTED UNDER THE PROTAGONIST THERAPEUTICS AMENDED AND RESTATED INDUCEMENT PLAN, WHICH WAS ADOPTED MAY 29, 2018, AND AMENDED FEBRUARY 18, 2020 AND FEBRUARY 15, 2022.

PROTAGONIST THERAPEUTICS REPORTS GRANTING OF INDUCEMENT AWARDS

ICOTYDE FIRST FULL QUARTER OF COMMERCIAL SALES WITH STRONG EARLY ADOPTION RUSFERTIDE NDA UNDER PRIORITY REVIEW FOR POLYCYTHEMIA VERA; PDUFA DATE IN AUGUST 2026 COMPREHENSIVE PHASE 2B PROGRAM WITH PN-881, AN ORAL IL-17 ANTAGONIST FOR PSORIASIS, PLANNED TO INITIATE EARLY Q1 2027 PHASE 1 STUDY INITIATED WITH PN-477SC, A TRIPLE GLP1/GIP/GCG AGONIST PEPTIDE FOR OBESITY CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $849.5 MILLION AS OF JUNE 30, 2026 NEWARK, CA / ACCESS NEWSWIRE / AUGUST 5, 2026 / PROTAGONIST THERAPEUTICS (NASDAQ:PTGX) ("PROTAGONIST" OR "THE COMPANY") TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026 AND PROVIDED A CORPORATE UPDATE. "THE SECOND QUARTER OF 2026 MARKED A DEFINING GROWTH PHASE FOR PROTAGONIST WITH A SUCCESSFUL COMMERCIAL LAUNCH OF ICOTYDE THROUGH OUR STRATEGIC PARTNER AND ACCELERATING MOMENTUM ACROSS OUR INTERNAL R&D PIPELINE.

PROTAGONIST REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NEWARK, CA / ACCESS NEWSWIRE / AUGUST 4, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) TODAY REPORTED THAT ON JULY 31, 2026, IT GRANTED INDUCEMENT AWARDS TO TWO RECENTLY HIRED EMPLOYEES IN ACCORDANCE WITH THE TERMS OF THEIR EMPLOYMENT OFFER LETTERS. THE AWARDS WERE GRANTED UNDER THE PROTAGONIST THERAPEUTICS AMENDED AND RESTATED INDUCEMENT PLAN, WHICH WAS ADOPTED MAY 29, 2018, AND AMENDED FEBRUARY 18, 2020 AND FEBRUARY 15, 2022.

NEWARK, CA / ACCESS NEWSWIRE / JULY 16, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) TODAY REPORTED THAT ON JULY 15, 2026, IT GRANTED INDUCEMENT AWARDS TO THREE RECENTLY HIRED EMPLOYEES IN ACCORDANCE WITH THE TERMS OF THEIR EMPLOYMENT OFFER LETTERS. THE AWARDS WERE GRANTED UNDER THE PROTAGONIST THERAPEUTICS AMENDED AND RESTATED INDUCEMENT PLAN, WHICH WAS ADOPTED MAY 29, 2018, AND AMENDED FEBRUARY 18, 2020 AND FEBRUARY 15, 2022.

NEWARK, CA / ACCESS NEWSWIRE / JULY 1, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) TODAY REPORTED THAT ON JUNE 30, 2026, IT GRANTED INDUCEMENT AWARDS TO THREE RECENTLY HIRED EMPLOYEES IN ACCORDANCE WITH THE TERMS OF THEIR EMPLOYMENT OFFER LETTERS. THE AWARDS WERE GRANTED UNDER THE PROTAGONIST THERAPEUTICS AMENDED AND RESTATED INDUCEMENT PLAN, WHICH WAS ADOPTED MAY 29, 2018, AND AMENDED FEBRUARY 18, 2020 AND FEBRUARY 15, 2022.

NEWARK, CA / ACCESS NEWSWIRE / JUNE 16, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) TODAY REPORTED THAT ON JUNE 15, 2026, IT GRANTED INDUCEMENT AWARDS TO THREE RECENTLY HIRED EMPLOYEES IN ACCORDANCE WITH THE TERMS OF THEIR EMPLOYMENT OFFER LETTERS. THE AWARDS WERE GRANTED UNDER THE PROTAGONIST THERAPEUTICS AMENDED AND RESTATED INDUCEMENT PLAN, WHICH WAS ADOPTED MAY 29, 2018, AND AMENDED FEBRUARY 18, 2020 AND FEBRUARY 15, 2022.

NEWARK, CA / ACCESS NEWSWIRE / JUNE 1, 2026 / PROTAGONIST THERAPEUTICS, INC. ("PROTAGONIST" OR THE "COMPANY") TODAY ANNOUNCED THAT FOUR ABSTRACTS HIGHLIGHTING RUSFERTIDE IN POLYCYTHEMIA VERA (PV) WILL BE PRESENTED AT THE 2026 EUROPEAN HEMATOLOGY ASSOCIATION CONGRESS (EHA2026 CONGRESS), TAKING PLACE JUNE 11-14, 2026, IN STOCKHOLM, SWEDEN. THE PRESENTATIONS INCLUDE ANALYSES FROM THE RANDOMIZED, CONTROLLED PHASE 3 VERIFY STUDY, AS WELL AS LONG-TERM RESULTS FROM THE PHASE 2 REVIVE AND THRIVE OPEN-LABEL EXTENSION STUDIES.

PROTAGONIST THERAPEUTICS TO PRESENT PHASE 3 VERIFY AND LONG-TERM RUSFERTIDE DATA AT THE 2026 EUROPEAN HEMATOLOGY ASSOCIATION CONGRESS

NEWARK, CA / ACCESS NEWSWIRE / MAY 28, 2026 / PROTAGONIST THERAPEUTICS (NASDAQ:PTGX) ("PROTAGONIST" OR "THE COMPANY") TODAY ANNOUNCED THAT DINESH V. PATEL, PH.D.

PROTAGONIST THERAPEUTICS TO PARTICIPATE IN TWO INVESTMENT BANK CONFERENCES IN JUNE 2026

ICOTYDE (ICOTROKINRA) APPROVED BY FDA IN MARCH FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS, TRIGGERING A $50 MILLION MILESTONE PAYMENT; PROTAGONIST RECEIVES TIERED ROYALTIES OF 6% TO 10% AND IS ELIGIBLE FOR UP TO $580 MILLION IN FUTURE MILESTONE PAYMENTS RUSFERTIDE NDA ACCEPTED AND GRANTED PRIORITY REVIEW BY FDA, WITH A PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE IN THE THIRD QUARTER OF 2026 PROTAGONIST EXERCISED ITS RUSFERTIDE OPT-OUT RIGHT UNDER THE TAKEDA COLLABORATION ON APRIL 28, TRIGGERING A $200 MILLION OPT-OUT FEE PAYABLE TO THE COMPANY; ELIGIBLE FOR ADDITIONAL $200 MILLION OPT-OUT AND $75 MILLION MILESTONE PAYMENTS UPON NDA APPROVAL, SALES MILESTONES OF UP TO $775 MILLION AND WORLDWIDE ROYALTIES RANGING FROM 14% TO 29% PN-881 (ORAL IL-17 ANTAGONIST PEPTIDE) PHASE 1 STUDY COMPLETION BY MID-2026 AND PHASE 2 INITIATION ANTICIPATED BY YEAR-END; PN-477SC AND PN-477O (SC AND ORAL TRIPLE GLP/GIP/GICG AGONIST) PHASE 1 INITIATION EXPECTED IN MID-2026 AND Q1 2027, RESPECTIVELY CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $620 MILLION AS OF MARCH 31, 2026, ANTICIPATED TO PROVIDE CASH RUNWAY THROUGH AT LEAST 2028 NEWARK, CA / ACCESS NEWSWIRE / MAY 5, 2026 / PROTAGONIST THERAPEUTICS (NASDAQ:PTGX) ("PROTAGONIST" OR "THE COMPANY") TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A CORPORATE UPDATE. "THE FIRST QUARTER OF 2026 MARKED A SERIES OF LANDMARK ACHIEVEMENTS FOR PROTAGONIST, HIGHLIGHTED BY THE U.S. APPROVAL OF ICOTYDE, FDA GRANTING PRIORITY REVIEW FOR RUSFERTIDE, AND ADVANCEMENT OF OUR HIGHLY DIFFERENTIATED AND FULLY-OWNED PEPTIDES PN-881 AND PN-477," SAID DINESH V.

PROTAGONIST REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

OPT-OUT ELECTION MAKES PROTAGONIST ELIGIBLE FOR $200 MILLION UPON EXERCISE AND AN ADDITIONAL $200 MILLION UPON FDA APPROVAL OF RUSFERTIDE FOR POLYCYTHEMIA VERA APPROVAL WOULD ALSO TRIGGER A $75 MILLION MILESTONE PAYMENT, BRINGING TOTAL POTENTIAL CASH TIED TO THE OPT-OUT ELECTION AND APPROVAL TO $475 MILLION PROTAGONIST BECOMES ELIGIBLE FOR UP TO $975 MILLION IN MILESTONE PAYMENTS AND TIERED ROYALTIES RANGING FROM 14% TO 29% ON WORLDWIDE NET SALES NEWARK, CA / ACCESS NEWSWIRE / APRIL 28, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) ("PROTAGONIST" OR THE "COMPANY") TODAY ANNOUNCED THAT IT HAS EXERCISED ITS RIGHT TO OPT OUT OF THE 50:50 U.S. PROFIT AND LOSS SHARING ARRANGEMENT UNDER ITS WORLDWIDE LICENSE AND COLLABORATION AGREEMENT WITH TAKEDA FOR RUSFERTIDE, AN INVESTIGATIONAL FIRST-IN-CLASS HEPCIDIN MIMETIC PEPTIDE UNDER U.S. FOOD AND DRUG ADMINISTRATION (FDA) PRIORITY REVIEW FOR THE TREATMENT OF ADULTS WITH POLYCYTHEMIA VERA (PV). BY EXERCISING ITS OPT-OUT RIGHT DURING THE CONTRACTUAL OPT-OUT PERIOD, PROTAGONIST BECOMES ELIGIBLE TO RECEIVE UP TO $400 MILLION IN OPT-OUT PAYMENTS, CONSISTING OF $200 MILLION PAYABLE UPON THE OPT-OUT ELECTION AND A FURTHER $200 MILLION PAYABLE UPON FDA APPROVAL OF RUSFERTIDE FOR THE TREATMENT OF ADULTS WITH PV.

PROTAGONIST EXERCISES RUSFERTIDE U.S. OPT-OUT RIGHT UNDER TAKEDA COLLABORATION

NEWARK, CA / ACCESS NEWSWIRE / APRIL 16, 2026 / PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) TODAY REPORTED THAT ON APRIL 15, 2026, IT ISSUED INDUCEMENT AWARDS TO TWO RECENTLY HIRED EMPLOYEES IN ACCORDANCE WITH THE TERMS OF THEIR EMPLOYMENT OFFER LETTERS. THE AWARDS WERE GRANTED UNDER THE PROTAGONIST THERAPEUTICS AMENDED AND RESTATED INDUCEMENT PLAN, WHICH WAS ADOPTED MAY 29, 2018, AND AMENDED FEBRUARY 18, 2020 AND FEBRUARY 15, 2022.

Protagonist Therapeutics, Inc.

PTGX

Price

Financial Reports

No items found.

Press Releases

Protagonist Therapeutics, Inc.

PTGX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PTGX